gliquidone
Small moleculeexperimental
Gliquidone is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany). — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Dec 16, 2003 (NCT00568074)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
KCNJ11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C- Mol. weight
- 527.64 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGliquidone ↗
- ChEMBLCHEMBL383634 ↗
Also known as
- 1-cyclohexyl-3-(p-beta-(4,4- dimethyl-2-methoxy-1,3-(2h,4h)-isoquinolinedione- 2-yl)phenethyl)sulfonylurea
- ar-df 26
- ardf-26
- ardf-26
- beglynor
- beglynor
- beglynora
- glikvidon
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone
- gliquidone calcium
- gliquidone, calcium salt
- gliquidone monosodium
- gliquidone, monosodium salt
- gliquidone sodium
- glurenor
- glurenorm
- glurenorm
- glurenorm
- glurenorm
- glurenorm
- glycvidon
- sanofi synthelabo brand of gliquidone
- yamanouchi brand of gliquidone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00568074 | Phase 4 | Dec 16, 2003 | Novo Nordisk |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1